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ABSTRACT
Stem cells are undifferentiated cells and can self-renew and 
differentiate into various cell types, besides having immuno-
modulating properties and paracrine effects in response to 
tissue injury, and may therefore treat injuries and diseases or 
even replace damaged or lost cells. Adipose tissue is an at-
tractive source of adult stem cells, since the human body has 
a large reserve that is obtained in large amounts by minimally 
invasive methods. Interest in these cells has been increasing 
steadily due to their properties and possible applications in 
regenerative medicine and cell therapy. A large part of these 
investigations are focused on cardiovascular diseases, which 
are a leading cause of morbidity and mortality worldwide. 
Although in recent years treatments have advanced in car-
diology, the development of new therapies to recover the 
damaged tissue still remains one of the main goals of cardiac 
research. However, to achieve effective results, in vivo and in 
vitro animal models for preclinical studies and consequently 
for application in humans must be standardized. The devel-
opment of preclinical models in large animals requires the 
use of well-characterized animal cell lines, similar to human 
cells, and the use of the porcine model represents a great 
advantage for preclinical translational research.
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RESUMO
Células-Tronco de Tecido Adiposo e a Importância 
da Padronização de um Modelo Animal para 
Experimentação Pré-Clínica
As células-tronco são células indiferenciadas, capazes de se 
autorrenovar e de se diferenciarem em diversos tipos celula-
res, além de apresentarem propriedades imunomoduladoras e 
efeitos parácrinos mediante injúria tecidual, podendo, dessa 
forma, tratar lesões e doenças ou ainda substituir células 
danificadas ou perdidas. Dentre as fontes de células-tronco 
adultas, o tecido adiposo é uma fonte atrativa, pois o organ-
ismo humano possui grande reserva desse tecido, que, por sua 
vez, é obtido em grandes quantidades por meio de métodos 
pouco invasivos. O interesse nessas células vem aumentando 
constantemente devido a suas propriedades e possíveis aplica-
ções na medicina regenerativa e terapia celular. Grande parte 
dessas pesquisas está voltada para doenças cardiovasculares, 
que são a principal causa de morbidade e mortalidade em 
todo o mundo. Embora nos últimos anos, os tratamentos em 
cardiologia tenham avançado, o desenvolvimento de novas 
terapias que recuperem o tecido danificado ainda permanece 
como um dos objetivos principais das pesquisas cardíacas. 
Porém, para obter resultados eficazes, é necessária a padroni-
zação de modelos animais in vivo e in vitro para estudos 
pré-clínicos e, consequentemente, a aplicação em humanos. 
O desenvolvimento de modelos pré-clínicos em animais de 
grande porte exige o uso bem caracterizado de linhagens de 
células animais semelhantes aos seus equivalentes humanos. 
O modelo suíno representa uma grande vantagem para a 
investigação translacional pré-clínica.
DESCRITORES: Células-tronco. Tecido adiposo. Doenças car-
diovasculares. Suínos. Modelos animais.
Zuttion et al. 
Stem Cells from Adipose Tissue
Rev Bras Cardiol Invasiva. 
2013;21(3):281-7
282
CELL CHARACTERIZATION 
For a cell population to be considered SCs, it 
must meet at least three requirements according to the 
International Society for Cellular Therapy: 
1. They have to be plastic-adherent, while main-
tained in culture conditions;
2. They have to be positive for CD105, CD73, and 
CD90, and negative for CD45, CD34, CD14, CD11b, 
CD79, or CD19 and HLA-DR.9 However, depending on 
the source from which they are obtained, the methods 
of cell isolation, and characteristics of the culture, the 
expression of these markers can occur differently. ASCs 
can also express other surface proteins such as CD44, 
CD71 (transferrin receptor), Stro-1 and fibronectin, 
vimentin, and CD73 (ecto-5’-nucleotidase, SH3, and 
SH4), among others.10,11 More studies are still needed 
to elucidate the expression variability of severalmarkers;
3. They have to be capable of differentiating into 
osteoblasts, chondrocytes, and adipocytes.9
MSC SOURCES
As previously stated, the bone marrow is the most 
common source of MSCs,12 but similar populations have 
also been obtained from other sources, such as umbili-
cal cord blood, placenta, amniotic fluid, dermis, liver, 
spleen, dental pulp,14 and adipose tissue.15
Among these sources, the adipose tissue stands 
out, which offers more advantages compared to other 
sources, due to its low risk for donors, higher number 
of MSCs (it is possible to collect 100 mL from 1 L of 
adipose tissue), and capability of maintaining their pro-
liferative potential for eight to ten passages without any 
detectable deterioration in their capacity of self-renewal, 
in addition to the absence of immunologic rejection.16
THE ADIPOSE TISSUE
Adipose tissue has mesodermal origin and contains 
a heterogeneous stromal cell population. The mesoderm 
arises during gastrulation as a medial layer between 
the endoderm and ectoderm. The embryonic mesoderm 
gives origin to several types of muscles – including the 
heart, all connective tissue, blood vessels, blood cells, 
and lymphatic vessels.15 Historically, adipose tissue 
was considered a metabolic reservoir for storage and 
release of energy substrates in the form of triglycerides 
and cholesterol, as well as fat-soluble vitamins. In the 
mid-1980s, this concept was modified, based on the 
identification of its role in sexual physiology through 
sexual steroids.17 The adipose tissue is a component 
of connective tissue with important functions, such as 
providing rigidity and resistance to tissues, maintaining 
thermal homeostasis, and assisting in visceral static. In 
S tem cells (SCs) are undifferentiated cells that can self-renew and differentiate into many cell types. In these processes of self-renewal and differentiation, 
the SCs can undergo two different types of division: 
(1) symmetrical division, in which the SC generates a 
new SC cell and a progenitor cell, and (2) asymmetrical 
division, in which the SC generates differentiated cells.1 
This process occurs while maintaining tissue homeostasis 
and the active SC niche. The niches are physiological 
microenvironments, consisting of specialized cells that 
signal and provide molecules on the cell surface to 
control the rate of proliferation of SCs, determining the 
differentiation of progenitor cells and protecting SCs from 
apoptosis. This reciprocal interaction between the SCs 
and the niche occurs in the early stages of embryonic 
development and is maintained during adulthood, and 
is essential for ontogeny and tissue repair.2
SCs are divided into two main types, according to 
their origin and plasticity. SCs may be of embryonic 
origin, that is, are isolated from the zygote or the in-
ner cell mass of the blastocyst, or they may be derived 
from the adult organism. Concerning the capacity of 
these cells to originate organism tissues, embryonic 
stem cells (ESCs) are classified as pluripotent, i.e., they 
are capable of generating all body cell types; whereas 
adult SCs (ASCs) have a more restricted differentiation 
potential, and are classified as multipotent.
ASCs were first described by Friendestein in 1970, 
who isolated in vitro stromal cells from bone marrow of 
mice. In that study, he demonstrated the morphological 
characteristics of cell expansion and differentiation.3 
Subsequently, in different culture conditions, it was 
observed that bone marrow ASCs were able to differ-
entiate into osteoblasts, chondrocytes, and adipocytes.4 
Based on this capacity to differentiate into different cell 
types, Caplan proposed in 1991 the term “mesenchymal 
stem cell” (MSC).5
The most studied source of MSCs is the bone mar-
row. MSCs from bone marrow, which represent a rare 
subpopulation (< 0.01% of the mononuclear cells from 
bone marrow) are a group of clonogenic cells, found in 
the bone marrow stroma and capable of differentiating 
not only into cells of mesodermal origin, but also into 
other non-mesodermal cell types, such as the neural 
and the hepatocytes.6
ASCs are known as multipotent, and differently 
from what was originally believed, they are not in-
volved only in the process of repair and homeostasis 
in tissues from which they are isolated, but also have 
several paracrine effects that contribute to the recovery 
and regeneration of other cell types and tissues in the 
body,7 as these cells produce and secrete a variety of 
cytokines, chemokines, and growth factors, which act 
in a paracrine manner in in vivo tissue regeneration.8 
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mammals, the predominant type of adipose tissue is the 
white type, compared to brown adipose tissue, which 
is found in neonates, but is virtually absent in adults.18 
This tissue is distributed in the body as subcutaneous 
white adipose tissue and white visceral adipose tissue, 
consisting of mature adipocytes, preadipocytes, fibro-
blasts, smooth muscle vascular cells, endothelial cells, 
resident monocytes, and macrophages and lymphocytes.19
According to Zannetino et al.,2 the niche of MSCs 
in adipose tissue is located in the perivascular region, 
and consists of blood vessels in association with con-
nective tissue, adipose stromal tissue, and many pro-
genitor cells and SCs (Figure 1). It may be stated that 
the adipose tissue SC niche is perivascular. Although 
the term “perivascular” means “around blood vessels”, 
adipose tissue SCs are also found within the vessels, as 
a part of the blood vessel wall components. However, 
due to the lack of specific markers, the exact location 
and cell identity are still elusive. 
The vascular network plays a role in adipogenesis. 
During embryonic development, the formation of capil-
laries is a decisive and specific phase in the development 
of adipose lobules, and an adequate vascularization is 
required for optimal functioning of the adipose tissue 
as a metabolic and endocrine organ. In addition, the 
adipogenic lineage cells secrete potent angiogenic fac-
tors, such as monobutyrin, vascular endothelial growth 
factor, leptin, and adiponectin. Finally, anti-angiogenic 
factors promote the loss of adipose tissue, thereby 
demonstrating the importance of angiogenesis for the 
maintenance of adipogenesis.20-22 However, large quanti-
ties of SCs can be isolated from this vascular fraction 
through the enzymatic digestion method.
ISOLATION OF MCS FROM ADIPOSE TISSUE
In 1964, Martin Rodbell23 established the in vitro 
isolation method of mature adipocytes and adipogenic 
progenitor cells from adipose tissue of rats. In his 
protocol, the tissue was fragmented and digested with 
type I collagenase enzyme at 37°C and the material 
was then centrifuged. The supernatant contained mature 
adipocytes and the pellet had components of vascular 
stromal fraction, including adipocyte progenitor cells 
and hematopoietic lineage cells. 
As in many fields with a rapid development, a num-
ber of names have been used for describe the adherent 
cell population, isolated from the enzymatic digestion 
by collagenase from adipose tissue, such as lipoblast, 
pericytes, pre-adipocyte, processed lipoaspirate, adipose 
tissue-derived stromal SC, adipose tissue-derived ASC, 
adipose tissue-derived stromal adult cell, adipose tissue-
derived multipotent SC, and adipose tissue MSC (Figure 
2A to 2C). The International Fat Applied Technology 
Society (IFATS) proposed a standardized nomenclature 
in Pittsburgh in 2004, adopting the term ASC, or adi-
pose stem cell, to refer to the population of adherent 
multipotent cells isolated from the vascular stromal 
fraction.24 The adipose tissue MSCs were isolated and 
characterized in humans and in animal species.13,25-30
ADIPOSE TISSUE MSCS
Similarly to the bone marrow, the adipose tissue 
MSCs have a broad differentiation potential in several 
different cell types, such as adipogenic, chondrogenic, 
osteogenic, (Figure 2D to 2F), myogenic, angiogenic, 
neurogenic, myogenic and cardiomiogenic.31 Nevertheless, 
the isolation success rate is 100% and the adipose tissue 
yield is 40 times higher than that of bone marrow.32 
Furthermore, the quantity of cells does not appear to 
decrease with age, making this type of cell attractive 
for the isolation of MSCs and progenitor cells.33
The MSCs have the capacity to accumulate around 
inflammatory processes when administered in vivo, due 
to their chemotactic properties. Therefore, these cells 
can be used in several areas, such as in regenerative 
therapy.7 Currently, cells with characteristics similar 
to those of human MSCs were isolated in vitro from 
several animals (pigs,34-38 dogs,39 sheep40). These animals 
are often used in regenerative medicine research as 
animal models for osteoarticular diseases,41 spinal cord 
injury,42 and myocardial infarction.37
REGENERATIVE MEDICINE
As shown above, adipose-tissue SCs exhibit abundant 
capacity of expansion in vitro and, more importantly, 
can originate cells of different cell lineages and even 
cardiomyocytes,32,43 in addition to the absence of ethical 
Figure 1. Figure illustrating adipose tissue-derived adult stem cell niche.
Source: Irina Kerkis
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questions regarding their use. Therefore, adipose tissue 
has become a very attractive source of MSCs for regen-
erative medicine, and cardiology is one of the areas 
in which these cells are very frequently employed.6
The leading cause of death worldwide due to non 
communicable diseases is cardiovascular disease (48%), 
such as myocardial infarction and congestive heart fai-
lure.44 Other diseases also cause myocardial dysfunction, 
such as Chagas disease and other cardiomyopathies.45
Advances in the treatment of cardiovascular dis-
eases are due, in part, from the development of coron- 
ary revascularization techniques, and pacemaker and 
defibrillator implantation. With the exception of heart 
transplantation, these treatment options are limited 
by their incapacity to substitute lost cardiomyocytes 
and myocardial scars, and this is aggravated by the 
incapacity of the heart to replace its cell mass through 
self-renewal. New treatment approaches are neces-
sary;46 alternatively, SC therapy has been proposed 
to generate new cardiomyocytes.47 Some studies have 
demonstrated the capacity of adipose tissue and bone 
marrow MSCs to differentiate into cardiomyocytes.48-50 
However, some studies have shown that the differenti- 
ation of MSCs into cardiomyocytes, when injected into 
the heart muscle, is arare event, demonstrating that the 
MSCs are not capable of generating cardiomyocytes in 
sufficient amounts to repair myocardial injury.51 How-
ever, the MSCs have not only an autocrine, but also a 
paracrine property, that is, when the MSCs are injected, 
they secrete factors (vascular endothelial growth factor, 
basic fibroblast growth factor, hepatocyte growth fac-
tor, insulin-like growth factor 1, and adrenomedullin), 
which play an anti-apoptotic, pro-angiogenic role and 
have an endogenous reparative effect, in addition to 
exerting aparacrine action directly on cardiomyocytes, 
increasing their rate of survival.52
Another important biological process influenced 
by MSCs through their paracrine effects is neovas-
cularization. Recent preclinical studies with femur 
fractures in rats have demonstrated the angiogenic 
potential of SCs derived from human adipose tissue. 
After ASC transplantation, an increase of angiogenesis 
Figure 2 – Swine adipose tissue-derived stem cells. (A) Isolation of stem cells from adipose tissue. (B) Morphology of adipose tissue-derived stem cells. 
(C) Colony-forming unit assay in adipose tissue-derived stem cells. (D) Adipogenic differentiation. Note the cells with lipid droplets. (E) Osteogenic 
differentiation (von Kossa staining); mineralization can be observed. (F) Hematoxylin-eosin staining demonstrating the chondrogenic differentiation. 
Scale bars: A = 20 mm; B to F = 10 micrometers. A, B, and D = phase contrast. C, E, and F = optical microscopy. Source: Zuttion et al., 2013 
(unpublished data).
A
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and neovascularization around the area of endochon-
dral ossification occurred, as well as a significant 
increase of capillary density.53 In another study using 
pigs as an animal model, it was shown that eight 
weeks after intramyocardial MSC transplantation, 
there was improvement in left ventricular function. 
The researchers observed that, after the first week of 
transplantation, there was improvement in myocardial 
blood flow during diastole, which was directly related 
to blood vessel size increase. These results indicated 
the process of neovascularization as a consequence 
of significant cardiomyogenesis.54 This is due to the 
production and secretion by MSCs of factors such as 
nitric oxide, vascular endothelial growth factor, basic 
fibroblast growth factor, angiopoietin, and hepatocyte 
growth factors, among others. The action of these factors 
leads to migration and proliferation of endothelial cells 
and vascular smooth muscle cells, as well as increase 
and maturation of vessels and extracellular matrix 
synthesis. Thus, the MSCs would improve capillary 
density and act in the formation of collateral vessels.7 
However, despite much research on the differentiation 
potential of these cells in cardiomyocytes, studies are 
still necessary to understand these mechanisms.
ANIMAL MODEL USED IN SC RESEARCH
Since many years ago until the present day, several 
species of animals have been used as experimental 
subjects in scientific research, aiming to discover pro-
phylactic or treatment measures for many diseases.55,56
Around 1865, Claude Bernard57 started using ani-
mals as a study model for transposition of acquired 
knowledge to understand human physiology. In his 
study, Bernard57 sought physical and chemical changes 
that caused alterations in animals similar to human 
diseases. Small animals (mice, rats, hamsters, or ger-
bils) comprise more than 90% of the total species 
used in laboratories,48 but the ideal model for use in 
research would be the one that resembled the human 
being in their physiological, anatomical, and organic 
characteristics, which impacts the effectiveness of the 
obtained conclusions.57
Given this fact, many results of studies with SCs 
are inconclusive due to the practice of xenotransplan-
tation (transplantation of organs or cells from different 
species), because these cells are usually isolated from 
human beings58,59 and transplanted to other species, 
which complicates the study and understanding of 
their action in the body. Furthermore, few animals are 
similar to the human organism, which further reduces 
the understanding of SCs. Thus, it would be ideal to 
have an animal model that was similar to humans in 
anatomy, physiology and pathophysiology. According to 
Bustard and McClellan,60 the pig (Sus scrofa domesticus) 
has similarities with humans regarding odontology, renal 
morphology and physiology, visual acuity, eye structure, 
skin physiology and morphology, cardiovascular physi-
ology and anatomy, digestive physiology and anatomy, 
and immunology. These similarities are more distant in 
other models, such as dogs, rats, mice, and other species 
used in research.56 According to Tumbleson,61 pigs are 
an effective model for studies in biomedical research 
because, in addition to presenting structures and functions 
similar to that of the human, it has similarity regarding 
size, diet pattern, digestive physiology, dietary habits, 
kidney structure and function, lung vascular structure, 
distribution of coronary arteries, propensity for obesity, 
respiratory frequency, and social behavior; and it is a 
flexible animal model to determine the effects of acute 
and chronic exposures to alcohol, caffeine, tobacco, 
food additives, and environment pollutants. 
Regarding adipose tissue MSCs, the pig model 
would be ideal, because in addition to all the similarities 
with human being, this animal has a large reserve of 
adipose tissue,61 facilitating MSC isolation from adipose 
tissue and autologous or heterologous transplantation 
(transplantation of organs or cells to the same species), 
in order to evaluate the mechanism of action of these 
cells and human MSCs.
SWINE ADIPOSE TISSUE SCs
Several authors have performed the isolation of 
adipose tissue-derived SC in pigs. Such cells showed 
potential to differentiate into different mesodermal 
lineages, such as bone, cartilage, fat, muscle, and 
cardiomyocytes, and expressed different SC markers, 
showing similarities with human adipose tissue-derived 
MSCs.34-38 Interestingly, pigs are already widely used in 
this field regarding endovascular device implantation, 
such as stents.62,63 However, it is a good preclinical 
model to test the effect of SCs specifically in the area 
of SCs applied to cardiovascular diseases. 
Moreover, these cells isolated from pigs have been 
partially characterized regarding the expression of MSC 
markers, and therefore it is difficult to compare the 
benefits of these cells in an organism not similar to 
the human body.
FINAL CONSIDERATIONS
The MSCs isolated from adipose tissue have a wide 
differentiation potential and can be easily obtained in 
large quantities through minimally-invasive and low-pain 
methods. Furthermore, these cells are able to promote 
the immunomodulation of the immune system and have 
a paracrine effect capable of mobilizing molecules to 
regenerate injured tissue. However, much of the research 
on SCs is limited, due to the use of xenotransplant- 
ation and the lack of standardization of animal models 
that are anatomically and physiologically close to that 
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of the human body, for instance, pigs. Therefore, a 
greater knowledge of the action mechanism of these 
cells is necessary, in a physiological environment that 
reproduces the human organism. This fact has caused 
some clinical and therapeutic applications of SC to 
remain uncertain. In summary, the expectation of re-
generative medicine based on SC use depends on the 
knowledge of the mechanism of these cells and their 
effects on the body, as well as of the molecules, fac-
tors, and signalling cascades that control cell survival 
and proliferation – through contact with SCs. Therefore, 
the applicability of SCs depends mostly on the use of 
suitable models and well characterized SCs. Multiple 
solutions are likely to emerge from growing technologies 
in the SC and regenerative medicine area. Numerous 
innovations will change the practice of medicine through 
the recognition that living cells are able to perform a 
series of functions that drugs cannot provide.
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